No new approvals, withdrawals or safety communications affecting nephrology today.
KDIGO has published conclusions from a Controversies Conference on targeting B cells in immune-mediated kidney diseases — the territory covering rituximab and its successors in membranous nephropathy, lupus nephritis, ANCA-associated vasculitis and minimal change disease.
A Controversies Conference is a specific format and worth reading as one. It is convened precisely where evidence does not settle practice, and its output is a map of what is agreed, what is disputed and what needs studying — not a set of graded recommendations. For B-cell depletion in glomerular disease that is the honest position: rituximab is established in some indications, used off-label in others on thin evidence, and newer agents with deeper depletion are arriving faster than outcome data.
Read it for the disagreements rather than the conclusions. In this area the useful information is which questions the field considers open.
- No new approvals, recalls or safety communications for nephrology today
- Covers membranous nephropathy, lupus nephritis, ANCA vasculitis and beyond
- A Controversies Conference maps disagreement; it does not issue graded guidance
- Newer deeper-depleting agents are outpacing their outcome evidence
- Most useful for identifying which questions remain genuinely open
The statistics, in plain English
A Controversies Conference deliberately reports disagreement rather than resolving it by vote. That makes it less immediately actionable than a guideline and more honest where the evidence is thin — a graded recommendation built on low-certainty evidence conveys more confidence than the underlying data support.
Read the rest in the app
You have read your two free briefings this month. The app carries all 27 specialties, every morning, free — and this finding is waiting in it.
Scan to keep reading on your phone. No account needed to start.
Tomorrow morning, before your first patient
One edition a day for nephrology, written by the desk, every claim tied to its paper. Six minutes.
Get the app — free